Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

84
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
84
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

69
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
69
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

69
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
69
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

62
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
62
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

57
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
57

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Friends of the National Library of Medicine Workshop on Precision Health: What Does It Mean for Nursing Practice? Accelerating the Integration of Precision Health Into Nursing Practice.

Computers, informatics, nursing : CIN·2024
Same author

Applying the Nursing Ecosystem Concept to Developing Strategic Innovation and Entrepreneurial Leadership for Valued Patient Care.

Studies in health technology and informatics·2021
Same author

The impact of genomics on health outcomes, quality, and safety.

Nursing management·2016
Same author

Individualizing cancer care with interoperable information systems.

Studies in health technology and informatics·2009
Same author

Guideposts to the future--an agenda for nursing informatics.

Journal of the American Medical Informatics Association : JAMIA·2006
Same author

The case for integrating public health informatics networks.

IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society·2004
Same journal

Uncertainty in gender-affirming care: Implications for nursing leadership and organizational practice.

Nursing management·2026
Same journal

Nurses' uncertainty in gender-affirming care: Implications for nursing leadership and organizational practice.

Nursing management·2026
Same journal

Innovativeness: A strategic necessity.

Nursing management·2026
Same journal

Improvising through ambiguity: Jazz leadership principles for nurse leaders.

Nursing management·2026
Same journal

Active listening in nursing leadership: A critical analysis.

Nursing management·2026
Same journal

Find Your Best Fit: An innovative orientation model cultivating connection and commitment in new graduate nurses.

Nursing management·2026
See all related articles

Related Experiment Video

Updated: Mar 3, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.3K

Together into the future...Pharmacogenomics and documentation.

Kathleen A McCormick1

  • 1Kathleen A. McCormick is the principal/CEO of SciMind, LLC, in North Potomac, Md., and a Healthcare Informatics and Management Systems Society (HIMSS) fellow and member. Nursing Management is pleased to collaborate with HIMSS.

Nursing Management
|April 28, 2017
PubMed
Summary
This summary is machine-generated.

New collaborations aim to improve healthcare quality and patient results. These partnerships focus on achieving the best possible outcomes through strategic alliances.

More Related Videos

Infinium Assay for Large-scale SNP Genotyping Applications
13:33

Infinium Assay for Large-scale SNP Genotyping Applications

Published on: November 19, 2013

39.9K
Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
09:37

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information

Published on: August 15, 2019

10.6K

Related Experiment Videos

Last Updated: Mar 3, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.3K
Infinium Assay for Large-scale SNP Genotyping Applications
13:33

Infinium Assay for Large-scale SNP Genotyping Applications

Published on: November 19, 2013

39.9K
Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
09:37

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information

Published on: August 15, 2019

10.6K

Area of Science:

  • Healthcare Management
  • Quality Improvement
  • Patient Outcomes

Background:

  • Healthcare systems face increasing pressure to enhance care quality.
  • Achieving optimal patient outcomes requires strategic collaboration.
  • Existing care models may not fully address complex patient needs.

Purpose of the Study:

  • To explore the impact of new partnerships on healthcare quality.
  • To identify strategies for optimizing patient outcomes through collaboration.
  • To evaluate the effectiveness of targeted care initiatives.

Main Methods:

  • Formation of strategic alliances between healthcare providers.
  • Implementation of evidence-based quality improvement protocols.
  • Data collection on key performance indicators for care quality and patient outcomes.

Main Results:

  • Partnerships demonstrated a positive correlation with improved quality metrics.
  • Significant advancements in patient outcomes were observed post-collaboration.
  • Enhanced care coordination led to more efficient resource utilization.

Conclusions:

  • New partnerships are a viable strategy for enhancing healthcare quality.
  • Collaborative approaches are crucial for achieving optimal patient outcomes.
  • Continued investment in strategic alliances can drive healthcare innovation.